During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Q3 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk’s deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector.  

In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as:  

Biotech capital markets: The XBI rose 7% in Q3, outperforming the S&P 500, driven by strong clinical readouts and strategic deals, with six IPOs showing strong investor demand. 

Private biotech markets: Venture financing dropped to $3.9B across 41 deals, with average deal size decreasing, while Series A and B deals led the market, showing renewed investor interest in early-stage companies. 

Strategic transaction activity: Licensing deal value fell by 22%, and M&A shifted to smaller deals focusing on early clinical-stage opportunities, with global deal values remaining down. 

Market outlook and advice for the months ahead: Locust Walk expects continued momentum in Q4 due to further Fed rate cuts, advises careful cash management, and foresees a stronger recovery by 2025. 

We invite you to listen to our podcast and read our report and welcome the opportunity to discuss its contents with you. 

Subscribe or follow Biotalk on Apple Podcasts | Spotify.